Crystalline forms of 'R- (R*,R*)!-2-(4-Fluorophenyl)-BETA, DELTA-dihydroxy5-(1-methylethyl)-3-Phenyl-4-'phenylam ino)carbonyl!-1H-pyrrole-1-heptanoic acid calcium salt (2:1)(atorvastatin)

Details for Australian Patent Application No. 2002258092 (hide)

Owner Warner-Lambert Company LLC

Inventors Byrn, Stephen, Robert; Krzyzaniak, Joseph, Francis; Li, Zheng, Jane; Gushurst, Karen, Sue; Park, Aeri; Coates, David, Andrew; Morrison, Henry, Grant, II; Vlahova, Petinka Ivanova

Agent Shelston IP

Pub. Number AU-B-2002258092

PCT Pub. Number WO2003/004470

Priority 60/302,049 29.06.01 US

Filing date 21 May 2002

Wipo publication date 21 January 2003

Acceptance publication date 17 May 2007

International Classifications

C07D 207/34 (2006.01) Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom

A61K 31/40 (2006.01) - having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

A61P 3/06 (2006.01) Drugs for disorders of the metabolism

A61P 19/10 (2006.01) Drugs for skeletal disorders

A61P 25/28 (2006.01) Drugs for disorders of the nervous system

Event Publications

22 May 2003 Application Open to Public Inspection

  Published as AU-B-2002258092

17 May 2007 Application Accepted

  Published as AU-B-2002258092

7 June 2007 Application for Amendment

  The nature of the amendment is: Amend the invention title to read Crystalline forms of [R-(R*,R*)]-2-(4-Fluorophenyl)-BETA, DELTA-dihydroxy5-(1-methylethyl)-3-Phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-hept anoic acid calcium salt (2:1)(atorvastatin). Address for service in Australia - Shelston IP Level 21 60 Margaret Street Sydney NSW 2000

9 August 2007 Application for Amendment

  The nature of the amendment is as shown in the statement(s) filed 24 May 2007. Address for service in Australia - Shelston IP Level 21 60 Margaret Street Sydney NSW 2000 Amendments, Section 104

20 September 2007 Amendment Made

  The nature of the amendment is: Amend the invention title to read Crystalline forms of [R-(R*,R*)]-2-(4-Fluorophenyl)-BETA, DELTA-dihydroxy-5- (1-methylethyl)-3-Phenyl-4-[phenylamino)carbonyl] - 1H-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)

18 October 2007 Standard Patent Sealed

10 January 2008 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 24 May 2007

17 December 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002258093-A PLANT FOR DRYING PAINTED SURFACES WITH PARTICULAR REFERENCE TO VEHICLES AND THEIR STRIPPED OWN PARTS AND THE VARIOUS CONTROL PROCEDURES USED

2002258091-FLOWMETER PROVING DEVICE AND METHOD